We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 3.21% | 2.25 | 2.16 | 2.40 | 2.25 | 2.20 | 2.20 | 618,502 | 09:58:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
TIDMIMM
RNS Number : 4650O
Immupharma PLC
18 August 2017
18 August 2017
ImmuPharma Plc
AIM Rule 17 Notice
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:
Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Ends
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance +44 (0)20 3861 Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKFDKABKDOFD
(END) Dow Jones Newswires
August 18, 2017 12:09 ET (16:09 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions